Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6349 USD | +26.90% | -8.00% | +11.39% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.39% | 19.65M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating